Navigation Links
Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe

BEDFORD, Mass., July 19, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX) announced today the pricing of its private placement of $1.0 billion in aggregate principal amount of its 6.25% Senior Notes due 2020 (the "Notes"). The offering is expected to close concurrently with the completion of Hologic's acquisition of Gen-Probe Incorporated (NASDAQ: GPRO). The acquisition is subject to the satisfaction of certain customary closing conditions, including obtaining the approval of Gen-Probe's stockholders. Gen-Probe has scheduled a Special Meeting of Stockholders for July 31, 2012 to vote on the pending acquisition and Hologic expects to close the acquisition on or about August 1, 2012.

Separately, Hologic announced that it has received expected pricing on its anticipated $2.80 billion of Senior Secured Credit Facilities to be obtained in connection with its acquisition of Gen-Probe. Those facilities are anticipated to comprise of the following:

  • $300 million revolving credit facility, initially at LIBOR plus 3.00%, due 2017;
  • $1.0 billion tranche A term loan facility, initially at LIBOR plus 3.00%, due 2017; and
  • $1.50 billion tranche B term loan facility, at LIBOR plus 3.50%, with a LIBOR floor of 1.00%, due 2019.

Hologic also expects to have the right to elect, from time to time, to have all or a portion of the facilities accrue interest at a base rate, to be defined, plus an applicable base rate margin. The margin applicable to the revolving credit facility and the tranche A loan facility is subject to adjustment based on changes in the total net leverage ratio to be specified in the definitive documentation for these facilities. The allocation of the principal amount, interest and the determination of the purchase price of the Senior Secured Credit Facilities are subject to change in limited circumstances, and the closing of the facilities is contingent on the satisfaction of certain conditions set forth in the definitive documentation for the facilities, including the closing of the Gen-Probe acquisition and there not having occurred, since December 31, 2011, an Acquired Business Material Adverse Effect (as defined in the definitive documentation for the facilities). The Senior Secured Credit Facilities are expected to close concurrently with the completion of Hologic's acquisition of Gen-Probe.

Based upon the pricing of the Notes and the expected pricing of the Senior Secured Credit Facilities, Hologic anticipates that the initial blended interest yield on the Company's total financing for the Gen-Probe acquisition will be approximately 4.80%, including the amortization of the original issue discount (OID) and excluding the impact of deferred financing costs.

Hologic intends to use the net proceeds from the Notes offering, together with amounts drawn under its new Senior Secured Credit Facilities and available cash, to acquire Gen-Probe and pay related fees and expenses.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States in accordance with Regulation S under the Securities Act. Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Notes.

About Hologic:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:
This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements with respect to the anticipated timing and completion of the Company's acquisition of Gen-Probe, and the anticipated closing and terms of the Company's financing for that acquisition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: the ability of Hologic to consummate the proposed acquisition of Gen-Probe in a timely manner or at all; satisfaction of the conditions precedent to consummation of the proposed acquisition, including the approval by Gen-Probe's stockholders; uncertainties relating to litigation, including pending and future Gen-Probe shareholder lawsuits related to the proposed acquisition; and the successful completion of all the other anticipated financing arrangements for the acquisition including the completion and funding of Hologic's proposed Senior Secured Credit Facilities, which may, among other things, be adversely affected by changes in prevailing credit markets (which have been subject to significant volatility), or adverse changes to Hologic's business or prospects, and the Company's ability to satisfy its conditions precedent for the closing of the issuance of its Notes. The risks included above are not exhaustive. Other factors that could adversely affect Hologic's business and prospects are described in the filings made by Hologic with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.


Hologic Investor Contact:                                                           
Deborah R. Gordon                                                                        
Vice President, Investor Relations                                           
(781) 999-7716                                                                                                                          

Hologic Media Contact:
Joele Frank / Andrew Siegel / Nicholas Lamplough
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Hologic to Release Third Quarter Fiscal 2012 Operating Results on Monday, July 30, 2012
3. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
4. Hologic, Inc. Announces Note Offering
5. Hologic And Gen-Probe Provide Update On Pending Transaction
6. Hologic and Gen-Probe Announce Clearance from German Federal Cartel Office for Hologics Acquisition of Gen-Probe
7. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Misonix Announces New Distribution Agreement For Panama
Post Your Comments:
(Date:11/30/2015)... Express Scripts (NASDAQ: ESRX ) today announced it will ... access to a low-cost alternative to Daraprim (pyrimethamine) , ... recently priced out of reach for people with HIV, pregnant ... --> --> Imprimis is offering a compounded ... acid) for $1 per capsule for people whose pharmacy benefit is ...
(Date:11/30/2015)... SINGAPORE , Nov. 30, 2015  QT Vascular ... Vascular", and together with its subsidiaries, TriReme Medical LLC ... global company engaged in the design, assembly and distribution ... of vascular disease, is pleased to announce that a ... Court of Appeals for the Federal Circuit ("Federal ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal ... announced the launch of Radiology Solutions, a fully ... Radiology Solutions comprises customized, data-driven practice management approaches ... to help radiology practices improve care delivery and ... 2015 Radiological Society of North America Annual Meeting ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold ... are collaborating with brands across various categories through traditional and social media marketing ... an elite group of Gold Medal Moms who can connect with today’s most ...
(Date:11/30/2015)... ... , ... The National Association of Professional Women (NAPW) honors ... Circle. She is recognized with this prestigious distinction for leadership in estate sales and ... than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome ...
(Date:11/30/2015)... ... November 30, 2015 , ... Being a caregiver for someone ... Maryland Health Care System, the Caregiver Support Program promotes the health and wellbeing ... job. Seventy-four percent report that their role as a caregiver has created marital ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase awareness of ... Your Mouth?” campaign to inform dentists that the technicians they trust could lack ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum ... summer, ushering in a new era of publicly accessible automated technology. Now, by ... continue to offer guests an up-close look at the shuttle at MOSI’s main ...
Breaking Medicine News(10 mins):